21 November 2022 - - Daniel Char, JD, has been appointed senior vice president and Chief Legal Officer at US-based ImmunoGen, Inc. (NASDAQ: IMGN), a specialist in the field of antibody-drug conjugates for the treatment of cancer, the company said.

Char joins ImmunoGen from Evelo Biosciences where he served as General Counsel and Secretary providing strategic counsel and operational support on a broad range of business and legal issues, including business development, commercialization, healthcare fraud, and intellectual property.

Prior to joining Evelo, Char was Associate General Counsel and Assistant Secretary at Smith+Nephew, after having served as General Counsel and secretary at Targanta Therapeutics, Senior Associate General Counsel at Idenix Pharmaceuticals, and Associate General Counsel at Biogen.

Char holds a JD from Harvard Law School and a BA in Economics from Tufts University.

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients.

Elahere (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.